Press Releases Gabather AB

Equities

GABA

SE0010869552

Market Closed - Nasdaq Stockholm Other stock markets 16:13:21 07/06/2024 BST			5-day change	1st Jan Change
1.815 ^SEK	-0.27%		+9.67%	+28.72%

05-30	Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-10	Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002	04-10	AQ
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders	03-18	AQ
Gabather reports initial positive results from the EEG/fMRI target engagement study	03-07	AQ
Gabather AB receives initial EEG data analysis from the GT-002 target engagement study	12-22	AQ
Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)	12-14	AQ
Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG	12-11	AQ
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	12/10/23	AQ
Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957	13/04/23	AQ
Gabather AB, receives Notice of Allowance from the U.S. Patent Office for its U.S. patent application publication No. US 2021/0087193 A1	07/06/22	AQ
BioStock: Gabather's lead candidate moves forward in the clinic	02/06/22	AQ
Gabather receives approval to start the EEG/fMRI target engagement study with the drug candidate GT-002	17/05/22	AQ
Gabather AB invited by the Alzheimer's Drug Discovery Foundation, USA to submit a grant application to expand the studies with GT-002 in preclinical models of Alzheimer's disease	22/03/22	AQ
BioStock: Gabather poised to complete phase I with GT-002	14/09/21	AQ
BioStock: Covid unmasks need for better mental health medication	10/05/21	AQ
BioStock Studio: Gabather gives clinical trial update	25/03/21	AQ
Gabather : enters into a research collaboration with leading US scientists to investigate GT-002 in a unique preclinical model of Alzheimer's Disease	24/03/21	AQ
BioStock: Q4 report points to progress in the clinic for Gabather	22/02/21	AQ
BioStock: Gabather - focus on CNS diseases	02/02/21	AQ
Gabather AB : submits a Clinical Trial Application to further advance the development of GT-002	22/01/20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW